- TickerINCY
- ISINUS45337C1027
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States
Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...
A director at Incyte Corp sold 20,000 shares at 81.080USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...
The independent financial analyst theScreener just slightly lowered the general evaluation of INCYTE (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 89.46 and its potential was estimated at USD 107.03.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Market In “Wait-And-See†Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...
A director at Incyte Corp sold 20,000 shares at 81.080USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...
Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...
ASGN is currently valued like it is a struggling staffing company, not that it is focused on staffing in some of the tightest labor markets right now in the midst of the At-Home world and the digitization of business. Markets are expecting UAFRS-based (Uniform) ROA (ROA') to decline by almost half, to lows not seen since emerging from the Great Recession in 2011, with slower growth for the company too. The market is viewing ASGN as a hyper cyclical staffing business, when, thanks to its positioning in areas like AI, machine learning, cloud, cybersecurity, and other tech focused areas, they ar...
Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...
The independent financial analyst theScreener just slightly lowered the general evaluation of INCYTE (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 89.46 and its potential was estimated at USD 107.03.